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MeOBJECTIVES This study sought to investigate the effect of treatment delay on microvascular reperfusion in
ST-segment elevation myocardial infarction (STEMI) patients from the large, multicenter, prospective HORIZONS-AMI
(Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial.
BACKGROUND Despite restoration of epicardial blood ﬂow during primary percutaneous coronary intervention (PCI),
one-third of patients do not obtain myocardial perfusion due to impairment in the microvascular circulation.
METHODS We examined the effect of symptom onset-to-balloon time (SBT) and door-to-balloon time (DBT) on
myocardial reperfusion during primary PCI in STEMI, utilizing resolution of ST-segment elevation (STR) and the
myocardial blush grade (MBG). The primary analysis was the relationships between SBT #2, >2 to 4, and >4 h and
DBT #1, >1 to 1.5, >1.5 to 2, and >2 h with MBG and STR. Clinical risk was assessed using a modiﬁed version of the
Thrombolysis In Myocardial Infarction risk score for STEMI.
RESULTS In 2,056 patients, absent microvascular perfusion (MBG 0/1) and STR (STR <30%) after primary PCI was
signiﬁcantly more common in patients with longer SBT, in patients with both low and high clinical risk proﬁles. By
multivariable analysis, SBT (p < 0.0001), anterior infarction (p < 0.0001), reference vessel diameter (p ¼ 0.005), lesion
minimum lumen diameter (p < 0.0001), hyperlipidemia (p ¼ 0.03), and current smoking (p ¼ 0.001) were independent
predictors of MBG 0/1, whereas SBT (p ¼ 0.007), anterior infarction (p < 0.0001), and history of renal insufﬁciency
(p ¼ 0.0002) were independent predictors of absent STR. DBT (p < 0.0001) was an independent predictor of MBG 0/1.
MBG 0/1 and STR<30% identiﬁed patients with increased 3-year mortality.
CONCLUSIONS The present study suggests that delay in mechanical reperfusion therapy during STEMI is associated
with greater injury to the microcirculation. (J Am Coll Cardiol Intv 2015;8:1966–74) © 2015 by the American College of
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1967AB BR E V I A T I O N S
AND ACRONYM S
DBT = door-to-balloon time
ECG = electrocardiogram
MBG = myocardial blush grade
PCI = percutaneous coronary
intervention
SBT = symptom onset-to-
balloon time
STEMI = ST-segment elevation
myocardial infarction
STR = ST-segment resolution
TIMI = Thrombolysis InT imely restoration of culprit artery patency,and thereby myocardial salvage, is the pri-mary objective of percutaneous coronary
intervention (PCI) in patients with ST-segment
elevation myocardial infarction (STEMI). In contem-
porary practice, normal (Thrombolysis In Myocardial
Infarction [TIMI] ﬂow grade 3) epicardial blood
ﬂow can be restored in the culprit vessel in approxi-
mately 90% of cases (1). However, tissue perfusion
at the level of the myocardium is not restored in
approximately one-third of patients (2), even after
successful primary PCI, due to impairment in micro-
vascular blood ﬂow; in these patients, the beneﬁtsSEE PAGE 1975
Myocardial Infarctionof reperfusion are limited (3). Small studies using car-
diac magnetic resonance imaging have shown that
prolonged duration of ischemia is associated with
larger areas of microvascular obstruction (4,5). Larger
observational studies have explored the relationship
between duration of ischemia and myocardial perfu-
sion, but these investigations have predated the
routine use of stents and modern antiplatelet therapy
(6), only reported a single-center experience (7), or
lacked core laboratory analysis. Moreover, there is a
paucity of data on the effect of door-to-balloon time
(DBT) on microvascular reperfusion. We, therefore,
examined the effect of symptom onset-to-balloon
time (SBT) and DBT on myocardial reperfusion from
a large contemporary multicenter, prospective study
of primary PCI in STEMI, utilizing 2 well-validated
measures of myocardial perfusion and reperfusion
success, namely, resolution of ST-segment elevation
(STR) (8–11) and myocardial blush grade (MBG) (12–15).
METHODS
STUDY POPULATION. The HORIZONS-AMI (Harmo-
nizing Outcomes with Revascularization and Stents in
Acute Myocardial Infarction) trial has been describedSTENTYS; is a consultant for Abbott Vascular, AstraZeneca, Bayer, Boston
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Manuscript received April 7, 2015; revised manuscript received July 14, 2015in detail (1). In brief, 3,602 patients presenting
with STEMIwithin 12 h of symptom onset were
randomized before angiography to bivalirudin
or heparin and a glycoprotein IIb/IIIa inhibitor
(1:1 ratio). Subsequently, 3,006 patients suit-
able for stenting were randomized again to a
drug-eluting stent or an identical bare-metal
stent (3:1 ratio). Independent adjudication of
clinical events and angiographic core labora-
tory analysis were performed at the Cardio-
vascular Research Foundation (New York,
New York). The primary analysis was the re-
lationships between SBT #2, >2 to 4, and >4 h
and DBT #1, >1 to 1.5, >1.5 to 2, and >2 h with
MBG and STR. We excluded 1,546 patients
from the analysis because of missing SBT, MBG, or STR
data.
DEFINITIONS. SBT was deﬁned as the time from
symptom onset until balloon inﬂation. DBT was
deﬁned as the time from arrival at the hospital (ﬁrst
hospital in transferred patients) until balloon inﬂa-
tion. Clinical risk was assessed using a modiﬁed
version of the TIMI risk score for STEMI (16). Selected
variables associated with high mortality were
assigned points weighted as follows: age $75 years
(3 points), age $65 years (2 points), Killip class II to
IV (2 points), anterior infarction (1 point), diabetes
mellitus (1 point), andweight<67 kg (1 point). For each
patient, points for each of these variables were sum-
med to give a modiﬁed TIMI clinical risk score (17).
ANGIOGRAPHIC ANALYSIS. Myocardial blush in the
distribution of the infarct vessel post-PCI was
analyzed using the methodology of van ’t Hof et al.
(13) at an independent angiographic core laboratory
(Cardiovascular Research Foundation) by investi-
gators blinded to the clinical variables. On the basis of
the maximal densitometric degree of contrast opaci-
ﬁcation, microvascular perfusion was scored as MBG
0/1 (no or minimal myocardial contrast opaciﬁcation),
MBG 2 (moderate contrast opaciﬁcation but less thanScientiﬁc, Covidien, CSL Behring, Janssen Pharma-
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1968in either an ipsilateral or contralateral noninfarct ar-
tery), and MBG 3 (normal myocardial blush or
contrast opaciﬁcation, comparable with the other
coronary arteries). When myocardial blush persisted
(“staining”), MBG 0 was assigned.
ST-SEGMENT ANALYSIS. Electrocardiograms (ECGs)
obtained pre-procedure and at 60-min post-procedure
were analyzed as pairs by the ECG core laboratory by
independent readers who were blinded to the clinical
and angiographic data. STR was evaluated using stan-
dardized techniques (8) and categorized as complete
(>70%), partial (30% to 70%), or none (<30%). All trial
patients in whom both baseline and 60-min post-PCI
ECG were available and interpretable were included
in this analysis. Patients with left bundle branch block
at baseline, paced ventricular rhythm, and patients
without ST-segment deviation in 2 or more contiguous
leads were excluded from ECG analysis.
STATISTICAL ANALYSIS. Continuous variables are
presented as median with interquartile range and
were compared using the Wilcoxon rank sum test.
Categorical variables are presented as proportions
and were compared using the chi-square or Fisher
exact test. Multivariable models were developed
using stepwise logistic regression with entry/stay
criteria of 0.1/0.1 to identify independent predictors
of MBG 0/1 and STR <30%. Candidate clinical vari-
ables were age, sex, diabetes mellitus, hypertension,
hyperlipidemia, current smoker, prior myocardial
infarction, prior PCI, prior coronary artery bypass
graft surgery, peripheral vascular disease, prior
angina, renal insufﬁciency, and Killip class. Angio-
graphic variables were number of diseased vessels,
baseline TIMI ﬂow grade 0/1, baseline reference
vessel diameter, baseline minimum lumen diameter,
baseline percent diameter stenosis, and culprit ar-
tery. Direct stenting was a procedural variable
included in the models. In addition to these, DBT and
SBT were added in separate models. An interaction
test between SBT and baseline and procedural vari-
ables on MBG 0/1 was performed. Variables included
were age, sex, history of angina, diabetes mellitus,
number of vessels treated, number of stents used,
and number of lesions treated. Cox proportional haz-
ard multivariable models were used to identify pre-
dictors of 3-year mortality. Variables included were
MBG, STR, age, sex, diabetes mellitus, smoking,
creatinine clearance, peripheral or cerebrovascular
disease, prior coronary artery bypass graft surgery or
PCI, PCI to left anterior descending artery, triple vessel
disease, and procedural success. The signiﬁcance level
was set at 0.05. All analyses were performed with SAS
version 9.2 (SAS Institute, Cary, North Carolina).RESULTS
BASELINE CLINICALANDPROCEDURAL CHARACTERISTICS.
There were 2,367 patients enrolled in the formal MBG
and STR substudy; however, only 2,056 had com-
plete SBT and DBT data available. Among these, 162
(7.9%), 976 (47.4%), and 918 (44.7%) patients pre-
sented within SBT of #2, >2 to 4, and >4 h, respec-
tively. There was no difference (p ¼ 0.48) in the
frequency of patients in the 3 groups who were and
were not included in the MBG and STR subanalyses
from the HORIZONS-AMI trial. The clinical charac-
teristics of patients with increasing duration of SBT
are summarized in Table 1. Patients with greater SBT
were older and were more likely to be women, have
diabetes mellitus, have prior angina, and have longer
DBT, but were less likely to have post-procedural
TIMI ﬂow grade 3 and procedural success.
RELATIONSHIP AMONG SBT, DBT, AND MYOCARDIAL
PERFUSION. As seen in Figure 1, absent microvas-
cular perfusion (MBG 0/1) after primary PCI was
signiﬁcantly more common in patients with longer
SBT. This relationship was similar in patients with
both a low (modiﬁed TIMI risk score <2; p ¼ 0.0002)
and high (modiﬁed TIMI risk score $2; p ¼ 0.0001)
clinical risk proﬁle. Similar relationships were present
between symptom-to-door time (SBT  DBT) and
myocardial perfusion (Online Figure 1). By multivar-
iable analysis, SBT, anterior infarction, reference
vessel diameter, lesion minimum lumen diameter,
hyperlipidemia, and current smoking were indepen-
dent predictors of MBG 0/1 (Table 2). With respect to
the relationship between SBT and MBG 0/1, signiﬁ-
cant interaction with baseline variables was only
observed for age (p < 0.001) such that the effect of
SBT was greater in younger patients.
Absent STR was also signiﬁcantly more frequent in
patients with longer SBT (Figure 1). This relationship
was present in patients with both a low (p < 0.0001)
and high (p ¼ 0.02) clinical risk proﬁle. By multivar-
iable analysis, SBT, anterior infarction, and history of
renal insufﬁciency were independent predictors of
absent STR (Table 2).
Figure 2 summarizes the relationships between
DBT and the 2 indexes of myocardial perfusion. DBT
>2 h was associated with a higher frequency of absent
microvascular perfusion (MBG 0/1), but there was no
relationship with between DBT and absent STR. By
multivariable analysis, DBT (odds ratio [OR]: 1.63;
95% conﬁdence interval [CI]: 1.16 to 2.30; p < 0.0001)
was an independent predictor of MBG 0/1.
When analyzed according to the SBT strata
(Figure 3), there were no statistically signiﬁcant
TABLE 1 Baseline Characteristics According to Symptom Onset-to-Balloon Time
SBT #2 h
(n ¼ 162)
SBT >2 to 4 h
(n ¼ 976)
SBT >4 h
(n ¼ 918)
Combined
(n ¼ 2,056)
p Value
All Groups
Age, yrs 54.1 (49.1–62.4) 58.3 (50.7–68.3) 61.4 (53.4–80.0) 59.2 (51.8–69.2) <0.0001
Men 85.2 (138/162) 77.0 (752/976) 74.8 (687/918) 76.7 (1,577/2,056) 0.02
Body mass index, kg/m2 27.13 (24.79–30.86) 27.13 (24.61–30.10) 27.00 (24.45–30.25) 27.06 (24.54–30.25) 0.75
Hypertension 51.2 (83/162) 49.1 (479/976) 53.5 (491/918) 51.2 (1,053/2,056) 0.16
Hyperlipidemia 46.9 (76/162) 43.3 (423/976) 41.5 (381/918) 42.8 (880/2,056) 0.39
Smoking 66.7 (108/162) 65.9 (641/973) 64.0 (584/912) 65.1 (1,333/2,047) 0.64
Diabetes mellitus 9.9 (16/162) 14.4 (141/976) 18.5 (170/918) 15.9 (327/2,056) 0.005
Prior myocardial infarction 9.3 (15/162) 10.2 (100/976) 10.5 (96/918) 10.3 (211/2,056) 0.90
Prior PCI 11.7 (19/162) 12.0 (117/976) 8.4 (77/917) 10.4 (213/2,055) 0.03
Prior coronary artery bypass
graft surgery
0.6 (1/162) 2.4 (23/976) 2.8 (26/918) 2.4 (50/2,056) 0.24
Prior angina 11.7 (19/162) 17.8 (174/976) 27.5 (252/917) 21.7 (445/2,055) <0.0001
History of congestive heart
failure
1.9 (3/162) 2.2 (21/976) 2.8 (26/918) 2.4 (50/2,056) 0.56
Killip class 1 95.1 (154/162) 91.1 (888/975) 90.3 (828/917) 91.0 (1,870/2,054) 0.15
Peripheral vascular disease 0.6 (1/162) 3.8 (37/975) 4.7 (43/918) 3.9 (81/2,055) 0.05
History of renal insufﬁciency 1.2 (2/162) 3.2 (31/975) 3.2 (29/918) 3.0 (62/2,055) 0.38
PCI to left anterior descending
artery
41.0 (71/173) 42.4 (446/1,052) 41.2 (412/1,000) 41.8 (929/2,225) 0.84
Pre-PCI TIMI 3 ﬂow 13.9 (24/173) 18.6 (196/1,051) 20.2 (202/999) 19.0 (422/2,223) 0.13
Post-PCI TIMI 3 ﬂow 97.1 (168/173) 95.1 (1,000/1,052) 88.9 (889/1,000) 92.4 (2,057/2,225) <0.0001
Clopidogrel administration 100.0 (162/162) 99.9 (975/976) 99.6 (914/918) 99.8 (2,051/2,056) 0.27
Glycoprotein IIb/IIIa inhibitor use 59.9 (97/162) 53.6 (523/976) 55.7 (510/915) 55.0 (1,130/2,053) 0.28
Drug-eluting stent 70.4 (112/159) 73.2 (687/939) 70.5 (606/859) 71.8 (1,405/1,957) 0.43
Bare-metal stent 30.8 (49/159) 28.0 (263/939) 30.7 (264/859) 29.4 (576/1,957) 0.41
Door-to-balloon time, min 58 (47–73) 93 (71–115) 120 (87–172) 98.00 (72–133) <0.0001
Procedural success* 90.8 (178/196) 90.3 (1,072/1,187) 82.7 (918/1,110) 87.0 (2,168/2,493) <0.0001
Left ventricular ejection
fraction, %
50.00 (45.00–55.00) 50.00 (45.00–59.00) 50.00 (40.00–58.00) 50.00 (43.00–58.00) 0.23
Values are median (interquartile range) or % (n/N). *TIMI ﬂow grade 3 plus residual stenosis <50%.
PCI ¼ percutaneous coronary intervention; SBT ¼ symptom onset-to-balloon time; TIMI ¼ Thrombolysis In Myocardial Infarction.
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1969differences in the rates of normal MBG and complete
STR when comparing those with DBT #90 min to
those with DBT >90 min. However, it is worth noting
that among the subgroup with SBT #2 h, those with
DBT #90 min had higher rates of MBG 3 and STR
>70% compared with patients with DBT >90 min. In
contrast, this trend was not seen in patients pre-
senting with SBT >2 h.
CLINICAL IMPLICATIONS OF MBG AND STR AFTER
PRIMARY PCI. The 3-year unadjusted mortality rates
were 2.6%, 4.4%, and 7.2% (p ¼ 0.007, log-rank test)
in the SBT #2, >2 to 4, and >4 h groups, respectively,
and 3.6%, 4.6%, 6.3%, and 6.6% (p ¼ 0.16) in the
DBT #1, >1 to 1.5, >1.5 to 2, and >2 h groups,
respectively. Online Figure 2 shows the 3-year mor-
tality according to the MBG and STR. MBG 0/1 and
STR <30% identiﬁed patients with increased mortal-
ity. In a multivariable model that included both MBG
0/1 and STR<30%, MBG 0/1 (OR: 1.79; 95% CI: 1.17 to
2.72; p ¼ 0.007) but not STR <30% (OR: 1.27; 95% CI:0.82 to 1.97; p ¼ 0.28) was an independent predictor
of 3-year mortality. Other independent predictors
were diabetes mellitus (OR: 2.13; 95% CI: 1.39 to 3.27;
p ¼ 0.0005), peripheral vascular disease (OR: 2.11;
95% CI: 1.16 to 3.86; p ¼ 0.01), history of smoking
(OR: 1.87; 95% CI: 1.21 to 2.89; p ¼ 0.005), and age
(OR: 1.30; 95% CI: 1.02 to 1.66; p ¼ 0.03).DISCUSSION
The major ﬁndings of the present study among STEMI
patients undergoing contemporary primary PCI are:
1) SBT is an independent predictor of impaired
myocardial perfusion, as assessed by both reduced
MBG and incomplete STR; 2) DBT is an independent
predictor of impaired MBG; 3) in early presenters
(SBT <2 h), reductions in DBT intervals might further
improve myocardial reperfusion; and 4) impaired
myocardial perfusion correlates with mortality at
3 years.
FIGURE 1 Symptom Onset-to-Balloon Time
Percent of patients with myocardial blush grade 0/1, 2, and 3 (left) and ST-segment resolution of <30%, 30% to 70%, and >70% (right)
according to the 3 symptom onset-to-balloon time groups.
Prasad et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 1 5 , 2 0 1 5
Ischemia Duration and Myocardial Perfusion D E C E M B E R 2 8 , 2 0 1 5 : 1 9 6 6 – 7 4
1970We observed a “time-dependent” relationship be-
tween SBT duration and the likelihood of impaired
myocardial perfusion following primary PCI. This
may be a potential pathophysiological factor that
might account for the higher mortality associated
with longer SBT. With respect to SBT duration, pa-
tients presenting within 2 h of symptom onset were
the least likely to have impaired myocardial perfu-
sion, whereas those presenting after 4 h had the
highest frequency of MBG 0/1 and STR <30%
(Figure 1). This is similar to the ﬁndings by Fokkema
et al. (7), who conducted a smaller single-center study
and reported an adverse effect of SBT on MBG andTABLE 2 Multivariable Predictors of Absent Myocardial
Perfusion in Models for SBT
Odds Ratio
95% Conﬁdence
Interval p Value
Predictors of MBG 0/1
SBT (>4 h vs. #2 h) 2.08 1.32–3.28 <0.0001
Anterior infarction 1.66 1.29–2.13 <0.0001
Reference vessel
diameter
1.38 1.10–1.73 0.005
Lesion minimum
lumen diameter
0.32 0.22–0.46 <0.0001
Hyperlipidemia 0.78 0.63–0.98 0.03
Current smoking 0.69 0.55–0.86 0.001
Predictors of STR <30%
SBT 1.27 1.06–1.51 0.007
Anterior infarction 2.10 1.63–2.72 <0.0001
History of renal
insufﬁciency
2.78 1.62–4.75 0.0002
MBG ¼ myocardial blush grade; SBT ¼ symptom onset-to-balloon time;
STR ¼ ST-segment resolution.STR with an apparent threshold at approximately 4 h.
The relationship between ischemia duration and
myocardial perfusion in our study was independent
of clinical characteristics and other angiographic
variables and was observed in those with low and
high clinical risk proﬁles. There was an interaction
between age and SBT on MBG such that the adverse
effect was seen in younger patients. Of note, despite
the universal use of stents in the present study, the
ﬁndings with regards to the relationship between SBT
and MBG resemble the observations from the prior
study by De Luca et al. (6), in which stents were used
in <60% of cases. This indicates that optimal epicar-
dial patency with routine use of stents does not
improve or worsen (by increasing distal embolization)
myocardial perfusion.
DBT is an important performance metric in the
management of STEMI. The present study provides
unique data regarding the relationship between DBT
and myocardial perfusion. A statistically signiﬁcant
impairment in MBG was detected in patients who had
a DBT >2 h, and this relationship was independent of
clinical and angiographic variables (Figure 2). These
data suggest that prolongation in DBT has an adverse
effect on microvascular salvage, although the data is
less compelling than that for SBT, because no rela-
tionship was detected between longer DBT and STR.
The reason that DBT was associated with one measure
of myocardial perfusion and not the other is unclear.
Because DBT is an integral component of SBT, we
examined the interaction between these 2 time met-
rics on myocardial perfusion (Figure 3). The present
study suggests that in early presenters (SBT <2 h),
DBT <90 min may result in a higher frequency of
FIGURE 2 Door-to-Balloon Time
Percent of patients with myocardial blush grade 0/1, 2, and 3 (left) and ST-segment resolution of <30%, 30% to 70%, and >70% (right)
according to the 4 door-to-balloon time groups.
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1971patients with MBG 3 and STR >70%, whereas no
additional effect of short DBT intervals was found in
patients with SBT >2 h. This assessment is consistent
with our prior analysis among patients in the
HORIZONS-AMI and CADILLAC (Controlled Abcix-
imab and Device Investigation to Lower Late Angio-
plasty Complications) trials (17). Among those who
presented after 90 min of symptom onset (repre-
senting the vast majority of STEMI patients), a short
(#90 min) DBT, compared with a longer DBT, had no
signiﬁcant effect on 1-year mortality. In contrast,
among patients with early time to presentation
(#90 min), a short DBT (#90 min) was associated with
signiﬁcantly lower 1-year mortality.FIGURE 3 Interaction Between Symptom Onset-to-Balloon and Doo
Percent of patients with normal myocardial perfusion (myocardial blush
according symptom onset-to-balloon time and door-to-balloon time (DAlthough microvascular injury may be a surrogate
for a larger infarct size, several studies have re-
ported an independent prognostic value of indexes
of myocardial perfusion (18,19). We have previously
demonstrated that both MBG and STR strongly
correlate with survival and that assessment of both
yields incremental prognostic information beyond
either measure alone (20). In the present study,
3-year mortality was signiﬁcantly higher among pa-
tients with MBG 0/1 and STR <30% (Online Figure 2),
with MBG as an independent predictor, which
highlights the adverse clinical effect of a closed
microcirculation in STEMI patients. There are likely
several mechanisms by which a longer duration ofr-to-Balloon Times
grade 3, left) and complete ST-segment resolution (>70%, right)
BT). p > 0.15 for all comparisons between DBT #90 and >90 min.
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1972ischemia leads to impaired myocardial perfusion.
These include distal macroembolization or micro-
embolization of thrombus, which becomes increas-
ingly organized with time and less responsive to
anticoagulant and antiplatelet therapies; local for-
mation of thrombus within the microcirculation; and
increased cellular and interstitial edema and hem-
orrhage (21,22). It remains to be established whether
these mechanisms are modiﬁable and whether
microvascular injury can be prevented or reversed.
Currently, there are limited therapeutic options that
speciﬁcally reduce microvascular injury. The recent
results of the TASTE (Thrombus Aspiration in ST-
Elevation Myocardial Infarction in Scandinavia) and
TOTAL (Trial of Routine Aspiration Thrombectomy
with PCI versus PCI Alone in Patientswith STEMI) trials
(23,24) investigating adjunctive aspiration thrombec-
tomy have been disappointing and have not conﬁrmed
previous reports (3). A strategy to reduce risk of
embolization, such as deferring stent placement in a 2-
staged procedure has shown beneﬁt in the small proof
of concept DEFER-STEMI (A Randomized Trial of De-
ferred Stenting Versus Immediate Stenting to Prevent
No- or Slow-Reﬂow in Acute ST-Segment Elevation
Myocardial Infarction) trial (25) while the routine use
of distal protection by a ﬁlterwire system during pri-
mary PCI (26), seemed not to improve microvascular
perfusion, infarct size, or prognosis. One might spec-
ulate that microvascular injury by embolization may
be a reason why some pharmacological strategies for
preventing reperfusion injury have been ineffective,
because a closed microcirculation would preclude de-
livery of any potential therapeutic agent to the target
site (21). On the contrary, several randomized trials
investigating pharmacological conditioning have re-
ported promising results, such as the periprocedural
regiments with exenatide (27) or cyclosporine infusion
(28). Intracoronary culprit lesion site delivery of
abciximabhas also recently shownpromise in reducing
infarct size (29). A better understanding of the role of
microvascular injury following STEMI is warranted to
develop novel therapies, and large randomized trials
such as the DANAMI-3 (Danish Study of Optimal Acute
Treatment of Patients with ST-elevation Myocardial
Infarction) (NCT01435408) are ongoing. Subgroup
analysis in late presenters in these trials would provide
valuable insight into pathophysiology and therapeutic
options.
STUDY LIMITATIONS. Our retrospective analysis is
subject to both recognized and unknown biases. The
observational design of the study allows us to report
an association between time to treatment and the
extent of impairment in myocardial perfusion, but wecannot establish a causal relationship. STR and MBG
were the only markers of myocardial perfusion
examined in the present study. Other imaging
modalities of microcirculatory function such as
contrast echocardiography, positron emission tomo-
graphic scanning, and invasive measures of coronary
ﬂow reserve (Doppler wire) may provide additional
insights regarding the effect of treatment delay on
microcirculatory function in patients with STEMI. We
attempted to statistically adjust for the many differ-
ence in the baseline clinical characteristics in patients
with longer SBT compared with those with a shorter
duration of ischemia; however, we cannot exclude
the possibility that measured or unmeasured con-
founders may have been responsible for the observed
relationship between longer SBT or DBT and impaired
myocardial perfusion.
CONCLUSIONS
The present study suggests that delay in mechanical
reperfusion therapy during STEMI is associated with
greater injury to the microcirculation. This relation-
ship appears more robust for the ischemia duration
(SBT) than for DBT. In early presenters, reducing
DBT may have a beneﬁcial effect on myocardial
perfusion; however, in patients with symptom
duration >120 min, the present ﬁndings of no addi-
tional beneﬁt of DBT reduction on myocardial
perfusion, as well as our prior report that DBT in
patients with SBT >90 min has little effect on mor-
tality (17), are in line with data suggesting that
decrease in median DBT in recent years has not
resulted in a reduction in mortality in STEMI pa-
tients (30,31). This highlights the need to reconsider
the role of DBT as a performance metric and
examine the utility of a broader metric of systems
delay such as ﬁrst medical contact to balloon time
(32) as well as total ischemic time. The latter re-
quires clinical trials focused on pre-hospital treat-
ment strategies, and perhaps revisiting public
education initiatives. Finally, recognizing that DBT
appears to have an insigniﬁcant effect on outcomes
in patients with SBT >90 min may improve care by
allowing physicians, in appropriate circumstances, to
focus on a more comprehensive clinical evaluation
to ensure diagnostic accuracy and assess key issues
such as comorbidities, bleeding risk, and appropri-
ateness of prolonged dual antiplatelet therapy.
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PERSPECTIVES
WHAT IS KNOWN? The goal of reperfusion therapy
in STEMI is to restore tissue perfusion, but this is not
achieved in approximately one-third of cases. Micro-
vascular injury is the major cause of this and is an
important determinant of prognosis; thus, under-
standing the pathophysiology of microvascular
dysfunction in STEMI may help in developing novel
treatment approaches.
WHAT IS NEW? In contemporary practice of primary
PCI, delay in reperfusion therapy, measured as the time
from symptom onset to mechanical reperfusion therapy,
is associated with greater microvascular injury. DBT, a
performance metric for STEMI, is also a determinant but
to a lesser extent.
WHAT IS NEXT? Continued efforts are required to
investigate treatment strategies aimed at preventing
microvascular injury in STEMI to determine if that im-
proves outcomes. This has proven to be an elusive goal to
date; moreover, there is a need to reconsider the current
focus on DBT as the primary quality metric and examine
the utility of broader time metrics such as ﬁrst medical
contact to balloon time and total ischemic time.
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